Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bicycle Therapeutics Q3 EPS $(0.96) Down From $(0.59) YoY

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.
byBenzinga Newsdesk
November 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Medtronic Presented Late-Breaking Data Showing Performance Of Its OmniaSecure Defibrillation Lead Met Its Primary Safety And Effectiveness Endpoints, Exceeding Prespecified Performance Goals, In The Global LEADR Pivotal Trial

By Benzinga Newsdesk
May 17, 11:37 AM
Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart RhythmDUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc

MDT